- Home
- CLLS vs EIC Comparison
CLLS vs EIC Comparison
Compare CLLS & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | EIC |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.6M | 293.8M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CLLS | EIC |
|---|---|---|
| Price | $4.71 | $11.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.50 | ★ $14.00 |
| AVG Volume (30 Days) | 112.6K | ★ 272.9K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | ★ 13.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | ★ $82,551,000.00 | $59,262,402.00 |
| Revenue This Year | $32.58 | $37.84 |
| Revenue Next Year | $20.68 | $23.33 |
| P/E Ratio | ★ N/A | $10.12 |
| Revenue Growth | ★ 129.04 | 44.30 |
| 52 Week Low | $1.10 | $10.81 |
| 52 Week High | $5.48 | $16.39 |
Technical Indicators
Market Signals| Indicator | CLLS | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 54.26 |
| Support Level | $4.47 | $11.35 |
| Resistance Level | $5.03 | $11.44 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 54.55 | 93.67 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.